BioSpace News Archive

BrickBio, the leader in site specific bioconjugation has launched a collaboration SiteSelect™ Panel for pharmaceutical and drug development partners to streamline ADC site optimization for all linker and payload combinations, delivering another platform to identify higher performing biologics.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), today announced that it will report its third-quarter 2021 financial results and provide an update on the cytisinicline development program on Tuesday, November 9, 2021, at 4:30 PM EST.

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter financial and operating results prior to market open on Tuesday, November 9, 2021.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are presenting at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional Beacon™ Optofluidic system to expand its antibody therapeutics capacity.

Anitoa Systems, LLC., a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing hardware, today announced its Maverick line of qPCR instruments have received US FDA registration and device listing as class II 510(k) exempt medical device.

Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA).

Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced that it has received two notices of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, JATENZO® (testosterone undecanoate).

The third calendar quarter of 2021 financial results continued to demonstrate Utah Medical Products, Inc.’s recovery after a time when there were restrictions on so-called nonessential medical procedures during the COVID-19 pandemic.

The latest quality inspection innovations for aerospace, medical, new energy vehicles, and additive manufacturing will be featured at the ZEISS booth, #1108, during The Quality Show in Chicago, IL, October 26-28, 2021.